The Sant Pau Research Institute (IR Sant Pau) has received a donation of 2,500 euros from the Viladecans Cancer Coordinator Association, aimed at boosting the research conducted by the centre on CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), a hereditary disease that affects the small blood vessels of the brain and can cause migraine, psychiatric disorders, recurrent strokes, and dementia. Despite recent progress, there is still no curative treatment.
The contribution from the Viladecans Cancer Coordinator Association will support the drug repositioning project led by the Pharmacogenomics and Neurovascular Genetics Research Group at IR Sant Pau, headed by Dr. Israel Fernández-Cadenas. The team investigates medicines already approved for other conditions that may have beneficial effects on CADASIL—an approach that can accelerate the development of potential therapies.
The support of organizations committed to research is essential to keeping active the study of rare diseases. Contributions like this one help facilitate the acquisition of materials, specialized analyses, and the development of new studies that enhance understanding of the disease and explore new therapeutic avenues.
IR Sant Pau expresses its deep gratitude to the Viladecans Cancer Coordinator Association for its trust and support. Their contribution is vital to continue advancing scientific knowledge and improving the quality of life of people affected by CADASIL and their families.
